3Maree AO, Fitzgerald DJ. Disease variable platelet response to aspirin and clopidogrel in atherothmmbotic disease [ J ]. Circulation, 2007, 115 (16): 2196-2207. 被引量：1
4Vane JR, Botting RM. The mechanism of action of aspirin [J]. Thromb Res, 2003, 110 (5 -6) : 255 -258. 被引量：1
5Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low - molecular - weight heparin: mechanisms of action, pharmacoki- netics, dosing, monitoring, efficacy and safety [J]. Chest, 2001, 119 (1 Suppl): 64S -94S. 被引量：1
6Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanisms of action, clinicaleffectiveness and optimal therapeutic range [J]. Chest, 2001, 119 (1 Suppl): 8S- 21S. 被引量：1
7Hirsh J, Fuster V, Ansell J, et al. AHA/ ACC foundation guide to warfarin therapy [J]. J Am Coil Cardiol, 2003, 41 (9): 1633 - 1652. 被引量：1
8Hirsh J, Anand SS, Halperin JL, et al. Guide to anticoagulant therapy: heparin, a statement for healtheare professionals [ J ]. Circulation, 2001, 103 ( 24 ) : 2994 - 3018. 被引量：1
9Tompkins C, Cheng A, Dalai D, et al. Dual antiplatelet therapy and heparin" bridging" significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter - defibrillator device implantation [J].J Am Coil Cardiol, 2010, 55 (21) : 2376 - 2382. 被引量：1
10Jamula E, Douketis JD, Schulman S. Perioperative anficoagulation in patients having implantation of a cardiac pacemaker or defibrillator: a systematic review and practical management guide [ J ]. J Thromb Haemost, 2008, 6 (10): 1615-1621. 被引量：1
